OPKO Health Income After Taxes 2010-2024 | OPK
OPKO Health income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
| OPKO Health Annual Income After Taxes (Millions of US $) |
|
|---|---|
| 2024 | $-53 |
| 2023 | $-189 |
| 2022 | $-328 |
| 2021 | $-30 |
| 2020 | $31 |
| 2019 | $-312 |
| 2018 | $-139 |
| 2017 | $-291 |
| 2016 | $-41 |
| 2015 | $-24 |
| 2014 | $-171 |
| 2013 | $-106 |
| 2012 | $-27 |
| 2011 | $-5 |
| 2010 | $-12 |
| 2009 | $-24 |
| OPKO Health Quarterly Income After Taxes (Millions of US $) |
|
|---|---|
| 2024-12-31 | $14 |
| 2024-09-30 | $25 |
| 2024-06-30 | $-10 |
| 2024-03-31 | $-82 |
| 2023-12-31 | $-66 |
| 2023-09-30 | $-84 |
| 2023-06-30 | $-20 |
| 2023-03-31 | $-18 |
| 2022-12-31 | $-85 |
| 2022-09-30 | $-86 |
| 2022-06-30 | $-101 |
| 2022-03-31 | $-55 |
| 2021-12-31 | $-73 |
| 2021-09-30 | $29 |
| 2021-06-30 | $-16 |
| 2021-03-31 | $31 |
| 2020-12-31 | $32 |
| 2020-09-30 | $24 |
| 2020-06-30 | $34 |
| 2020-03-31 | $-59 |
| 2019-12-31 | $-112 |
| 2019-09-30 | $-62 |
| 2019-06-30 | $-60 |
| 2019-03-31 | $-79 |
| 2018-12-31 | $-73 |
| 2018-09-30 | $-26 |
| 2018-06-30 | $1 |
| 2018-03-31 | $-41 |
| 2017-12-31 | $-215 |
| 2017-09-30 | $-32 |
| 2017-06-30 | $-11 |
| 2017-03-31 | $-32 |
| 2016-12-31 | $-34 |
| 2016-09-30 | $-14 |
| 2016-06-30 | $18 |
| 2016-03-31 | $-10 |
| 2015-12-31 | $3 |
| 2015-09-30 | $132 |
| 2015-06-30 | $-42 |
| 2015-03-31 | $-116 |
| 2014-12-31 | $-52 |
| 2014-09-30 | $-50 |
| 2014-06-30 | $-26 |
| 2014-03-31 | $-43 |
| 2013-12-31 | $-14 |
| 2013-09-30 | $-59 |
| 2013-06-30 | $-2 |
| 2013-03-31 | $-31 |
| 2012-12-31 | $0 |
| 2012-09-30 | $-9 |
| 2012-06-30 | $-10 |
| 2012-03-31 | $-8 |
| 2011-12-31 | $11 |
| 2011-09-30 | $-6 |
| 2011-06-30 | $-5 |
| 2011-03-31 | $-4 |
| 2010-12-31 | $3 |
| 2010-09-30 | $-5 |
| 2010-06-30 | $-6 |
| 2010-03-31 | $-4 |
| 2009-12-31 | $-3 |
| 2009-09-30 | $-6 |
| 2009-06-30 | $-6 |
| 2009-03-31 | $-9 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.930B | $0.713B |
| OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel. | |||